Zhejiang Shouxiangu Pharm Co (603896) - Net Assets
Based on the latest financial reports, Zhejiang Shouxiangu Pharm Co (603896) has net assets worth CN¥2.29 Billion CNY (≈ $335.24 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.22 Billion ≈ $470.95 Million USD) and total liabilities (CN¥927.41 Million ≈ $135.71 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Zhejiang Shouxiangu Pharm Co tangible book value ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.29 Billion |
| % of Total Assets | 71.18% |
| Annual Growth Rate | 23.97% |
| 5-Year Change | 39.53% |
| 10-Year Change | 417.35% |
| Growth Volatility | 34.86 |
Zhejiang Shouxiangu Pharm Co - Net Assets Trend (2012–2025)
This chart illustrates how Zhejiang Shouxiangu Pharm Co's net assets have evolved over time, based on quarterly financial data. See Zhejiang Shouxiangu Pharm Co defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Zhejiang Shouxiangu Pharm Co (2012–2025)
The table below shows the annual net assets of Zhejiang Shouxiangu Pharm Co from 2012 to 2025. For live valuation and market cap data, see market cap of Zhejiang Shouxiangu Pharm Co.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.26 Billion ≈ $330.77 Million |
-1.46% |
| 2024-12-31 | CN¥2.29 Billion ≈ $335.69 Million |
+5.65% |
| 2023-12-31 | CN¥2.17 Billion ≈ $317.73 Million |
+13.95% |
| 2022-12-31 | CN¥1.91 Billion ≈ $278.84 Million |
+17.62% |
| 2021-12-31 | CN¥1.62 Billion ≈ $237.06 Million |
+22.15% |
| 2020-12-31 | CN¥1.33 Billion ≈ $194.08 Million |
+13.12% |
| 2019-12-31 | CN¥1.17 Billion ≈ $171.57 Million |
+19.06% |
| 2018-12-31 | CN¥984.74 Million ≈ $144.10 Million |
+13.22% |
| 2017-12-31 | CN¥869.75 Million ≈ $127.27 Million |
+99.06% |
| 2016-12-31 | CN¥436.93 Million ≈ $63.94 Million |
+18.56% |
| 2015-12-31 | CN¥368.53 Million ≈ $53.93 Million |
+14.96% |
| 2014-12-31 | CN¥320.56 Million ≈ $46.91 Million |
+7.03% |
| 2013-12-31 | CN¥299.50 Million ≈ $43.83 Million |
+116.45% |
| 2012-12-31 | CN¥138.37 Million ≈ $20.25 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Zhejiang Shouxiangu Pharm Co's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5144.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.02 Billion | 45.00% |
| Other Components | CN¥1.24 Billion | 55.00% |
| Total Equity | CN¥2.26 Billion | 100.00% |
Zhejiang Shouxiangu Pharm Co Competitors by Market Cap
The table below lists competitors of Zhejiang Shouxiangu Pharm Co ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zhengzhou Coal Mining Machinery Group Company Limited
F:ZGC
|
$423.71 Million |
|
China Datang Corporation Renewable Power Co. Limited
F:DT7
|
$423.98 Million |
|
Shanghai HYP-ARCH Architectural Design Consultant Co.Ltd.
SHE:301024
|
$424.28 Million |
|
QingCloud Technologies Corp.
SHG:688316
|
$424.32 Million |
|
Shenzhen Hifuture Electric
SHE:002168
|
$423.42 Million |
|
Aic Mines Ltd
AU:A1M
|
$423.28 Million |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381
|
$423.24 Million |
|
Jiangnan Yifan Motor Co.Ltd
SHE:301023
|
$423.19 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhejiang Shouxiangu Pharm Co's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,294,019,344 to 2,259,518,517, a change of -34,500,827 (-1.5%).
- Net income of 18,174,274 contributed positively to equity growth.
- Dividend payments of 59,497,562 reduced retained earnings.
- Other comprehensive income decreased equity by 219,083,298.
- Other factors increased equity by 225,905,758.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥18.17 Million | +0.8% |
| Dividends Paid | CN¥59.50 Million | -2.63% |
| Other Comprehensive Income | CN¥-219.08 Million | -9.7% |
| Other Changes | CN¥225.91 Million | +10.0% |
| Total Change | CN¥- | -1.50% |
Book Value vs Market Value Analysis
This analysis compares Zhejiang Shouxiangu Pharm Co's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.28x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 11.07x to 1.28x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | CN¥1.32 | CN¥14.60 | x |
| 2013-12-31 | CN¥2.56 | CN¥14.60 | x |
| 2014-12-31 | CN¥2.35 | CN¥14.60 | x |
| 2015-12-31 | CN¥2.71 | CN¥14.60 | x |
| 2016-12-31 | CN¥3.20 | CN¥14.60 | x |
| 2017-12-31 | CN¥5.34 | CN¥14.60 | x |
| 2018-12-31 | CN¥5.35 | CN¥14.60 | x |
| 2019-12-31 | CN¥6.41 | CN¥14.60 | x |
| 2020-12-31 | CN¥7.20 | CN¥14.60 | x |
| 2021-12-31 | CN¥8.47 | CN¥14.60 | x |
| 2022-12-31 | CN¥9.81 | CN¥14.60 | x |
| 2023-12-31 | CN¥11.09 | CN¥14.60 | x |
| 2024-12-31 | CN¥11.55 | CN¥14.60 | x |
| 2025-12-31 | CN¥11.40 | CN¥14.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhejiang Shouxiangu Pharm Co utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.80%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.84%
- • Asset Turnover: 0.20x
- • Equity Multiplier: 1.45x
- Recent ROE (0.80%) is below the historical average (13.57%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 24.59% | 19.14% | 0.65x | 1.98x | CN¥20.19 Million |
| 2013 | 18.05% | 21.36% | 0.62x | 1.37x | CN¥24.10 Million |
| 2014 | 21.60% | 22.96% | 0.60x | 1.56x | CN¥37.19 Million |
| 2015 | 17.00% | 20.75% | 0.50x | 1.64x | CN¥25.79 Million |
| 2016 | 18.53% | 25.72% | 0.51x | 1.40x | CN¥37.29 Million |
| 2017 | 10.22% | 24.02% | 0.40x | 1.07x | CN¥1.91 Million |
| 2018 | 10.93% | 21.05% | 0.43x | 1.21x | CN¥9.18 Million |
| 2019 | 10.57% | 22.66% | 0.41x | 1.14x | CN¥6.65 Million |
| 2020 | 11.44% | 23.85% | 0.37x | 1.28x | CN¥19.08 Million |
| 2021 | 12.40% | 26.18% | 0.39x | 1.21x | CN¥38.86 Million |
| 2022 | 14.58% | 33.51% | 0.29x | 1.50x | CN¥87.23 Million |
| 2023 | 11.72% | 32.44% | 0.25x | 1.46x | CN¥37.35 Million |
| 2024 | 7.62% | 25.26% | 0.22x | 1.36x | CN¥-54.69 Million |
| 2025 | 0.80% | 2.84% | 0.20x | 1.45x | CN¥-207.78 Million |
Industry Comparison
This section compares Zhejiang Shouxiangu Pharm Co's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $604,930,526
- Average return on equity (ROE) among peers: 13.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhejiang Shouxiangu Pharm Co (603896) | CN¥2.29 Billion | 24.59% | 0.40x | $423.54 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $85.02 Million | 26.56% | 2.79x | $53.47 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $64.35 Million | 12.98% | 2.10x | $1.50 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $128.43 Million | -28.90% | 2.15x | $378.62 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $730.78 Million | -9.68% | 0.13x | $470.05 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.65 Billion | 1.65% | 0.84x | $1.54 Billion |
| Hualan Biological EngineeringInc (002007) | $94.10 Million | 30.66% | 1.57x | $3.43 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $626.21 Million | 14.40% | 0.46x | $1.14 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $170.01 Million | 48.10% | 0.80x | $4.52 Billion |
| Baolingbao Biology Co Ltd (002286) | $238.05 Million | 18.81% | 2.12x | $496.75 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $2.26 Billion | 16.10% | 0.32x | $1.64 Billion |
About Zhejiang Shouxiangu Pharm Co
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. engages in the selection, cultivation, processing, and sale of medicinal materials in China. It offers Ganoderma lucidum spore powder and brand broken cell wall powder, as well as broken wall Ganoderma lucidum spore powder granules and powder tablets; Tiepi Fengdou granules; and Tiepi Fengdou Ganoderma lucidum extracts. The company offers its products … Read more